TB drug deal offers short term solution, excludes high burden nations, says health advocacy group

“The deal remains just a stop-gap because bedaquiline will only be available to a limited number of countries that will be included in this agreement, procuring through the Global Drug Facility,” Christophe Perrin, TB advocacy pharmacist at Medecins Sans Frontieres (MSF) Access Campaign, said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rFxg5Uk
via IFTTT